Quick Answer
Raphael Pharmaceutical Inc. reported Net Income Loss of -$1.28 million for the year ending 2025.
- Raphael Pharmaceutical Inc. showed an increase of +15.8% in Net Income Loss from 2024 to 2025.
- This data is from Raphael Pharmaceutical Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$243.0 thousand | Q1 2021: -$255.0 thousand | Q2 2021: -$387.0 thousand | Q3 2021: -$416.0 thousand | Q1 2022: -$185.0 thousand | Q2 2022: -$627.0 thousand | Q3 2022: -$1.44 million | Q1 2023: -$264.0 thousand | Q2 2023: -$417.0 thousand | Q3 2023: -$725.0 thousand | Q1 2024: -$550.0 thousand | Q2 2024: -$248.0 thousand | Q3 2024: -$326.0 thousand | Q1 2025: -$429.0 thousand | Q2 2025: -$322.0 thousand | Q3 2025: -$255.0 thousand.
- Over the full 6 years of available data (2020 to 2025), Raphael Pharmaceutical Inc.'s Net Income Loss has declined by 78.1%.
- Historical annual values: Fiscal year 2025: -$1.28 million | Fiscal year 2024: -$1.52 million | Fiscal year 2023: -$1.34 million | Fiscal year 2022: -$3.36 million | Fiscal year 2021: -$1.62 million | Fiscal year 2020: -$718.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: